Bellevue Group’s Zymeworks ZYME Stock Holding History

Bellevue Group’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-18,400	Closed	-$653K	–	227
2020 Q1	$653K	Buy	+18,400	New	+$753K	0.01%	149

Other funds holding ZYME

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bellevue Group's ZYME Position: Q2 2020 in Review

Bellevue Group sold out of Zymeworks (ZYME) in Q2 2020, closing a stake of 18,400 shares — an estimated $653K sold.

Bellevue Group first reported a position in ZYME in Q1 2020 and held it in 1 quarter. The position peaked at $653K in Q1 2020. 133 funds tracked by Wall St. Rank hold ZYME as of Q2 2020.

Bellevue Group reported no remaining Zymeworks position as of Q2 2020 after selling out during the quarter.
Bellevue Group sold 18,400 Zymeworks shares in Q2 2020, an estimated $653K.
Bellevue Group first reported a position in Zymeworks in Q1 2020 and held it in 1 quarter.
Bellevue Group's Zymeworks position peaked at $653K in Q1 2020.
133 funds tracked by Wall St. Rank held Zymeworks as of Q2 2020.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.